Q2 2021

Filed Aug 16, 2021 · 10-Q · 47 days after period end · 0001583771-21-000008

Q2 2021 · 10-Q

Revenue

$0.00

— vs Q2 2020

Net Income

-$7.67M

N/M vs Q2 2020

EPS Diluted

-$0.10

N/M vs Q2 2020

Operating Income-$6,854,599N/M

Operating Cash Flow

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	$0.00	$0.00	—	—
Net Income	-$7.67M	-$4.94M	-$1.02M	-$4.03M
EPS Diluted	-$0.10	-$0.58	-$7.48	-$26.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR